Figure 2.
(A) Event-free survival (EFS) and (B) overall survival (OS) for patients treated with idarubicin and cytarabine with clofarabine (CIA), idarubicin and cytarabine with fludarabine (FIA), and an idarubicin and cytarabine (IA) historical cohort.